On the one hand, GSTM3 influences the malignant metabolic pattern in pancreatic cancer, alleviates aggressiveness in renal cell carcinoma, and reverses radioresistance in hepatocellular carcinoma to suppress tumour malignancy [25–27]. Here, GSTM3 is linked to hereditary clear cell renal cell carcinoma.